Anti-tumor immunotherapy via antigen delivery from a live attenuated genetically engineered Pseudomonas aeruginosa type III secretion system-based vector.
Détails
ID Serval
serval:BIB_4072164F6485
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Anti-tumor immunotherapy via antigen delivery from a live attenuated genetically engineered Pseudomonas aeruginosa type III secretion system-based vector.
Périodique
Molecular therapy
ISSN
1525-0016 (Print)
ISSN-L
1525-0016
Statut éditorial
Publié
Date de publication
11/2006
Peer-reviewed
Oui
Volume
14
Numéro
5
Pages
656-661
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Publication Status: ppublish
Résumé
Immunotherapy requiring an efficient T lymphocyte response is initiated by antigen delivery to antigen-presenting cells. Several studies have assessed the efficiency of various antigen loading procedures, including microbial vectors. Here a live strain of Pseudomonas aeruginosa was engineered to translocate a recombinant antigenic protein into mammalian cells via the type III secretion system, a bacterial device translocating effector proteins into host cells. Optimization of the vector included virulence attenuation and determination of the N-terminal sequence allowing translocation of fused antigens into cells. In vitro delivery of an ovalbumin fragment by the bacterial vector into dendritic cells induced the activation of ovalbumin-specific CD8(+) T lymphocytes. Mice injected with the ovalbumin-delivering vector developed ovalbumin-specific CD8(+) T lymphocytes and were resistant to a subsequent challenge with an ovalbumin-expressing melanoma. Moreover, in a curative assay, injection of the vaccine vector 5 and 12 days after tumor implantation led to a complete cure in five of six animals. These results highlight the utility of type III secretion system-based vectors for anti-tumor immunotherapy.
Mots-clé
Animals, Antigens/immunology, Cells, Cultured, Dendritic Cells/immunology, Genetic Engineering, Genetic Therapy, Genetic Vectors/genetics, Immunotherapy, Mice, Neoplasms/genetics, Neoplasms/immunology, Neoplasms/therapy, Pseudomonas aeruginosa/genetics
Pubmed
Web of science
Open Access
Oui
Création de la notice
29/04/2021 10:59
Dernière modification de la notice
17/07/2023 11:57